"isn't it true that Teva could not alter their manufacturing process partway thru this 7.5 yr ANDA process?"
Au contraire, they're gonna have to; the product is the process here. I don't think it's Codexis. They're into catalysts and enzymes. While the latter do play a roll in the manufacture of enoxaparin, it ain't nearly enough. They certainly have no IP or publications on oligosaccharide characterization. I think their deal with Teva was to optimize processes for easier stuff.
Market Data 
Markets 
AI
